OVID
$2.62+0.32 (+13.91%)
Ovid Therapeutics Inc., a biopharmaceutical company, engages in the development of impactful medicines for patients and families with epilepsies and seizure-related neurological disorders in the United States.
Historical Price
Peer Comparison
Whystock Valuation Model
Fundamentals
Ovid Therapeutics Inc., a biopharmaceutical company, engages in the development of impactful medicines for patients and families with epilepsies and seizure-related neurological disorders in the United States. The company is developing OV329, a GABA-...
Recent News
Ovid Therapeutics Q4 Earnings Call Highlights
Ovid Therapeutics (NASDAQ:OVID) outlined new pipeline and financing updates alongside its fourth-quarter and full-year 2025 results, highlighting regulatory clearance in Australia for its KCC2 direct activator OV4071, new safety and tolerability data for its seizure candidate OV329, and a $60 millio
Here's Why Ovid Therapeutics Stock Popped Higher Today
Ovid stock surged 18% following positive Phase 1 data for OV329, and investors are getting excited about a forthcoming Phase 2.
Exchange-Traded Funds, Equity Futures Lower Ahead of Key Economic Data, FOMC Meeting
The broad market exchange-traded fund SPDR S&P 500 ETF Trust (SPY) was down 0.3% and the actively tr
Ovid Therapeutics (OVID) Q4 Earnings and Revenues Surpass Estimates
Ovid Therapeutics (OVID) delivered earnings and revenue surprises of +158.71% and +195.47%, respectively, for the quarter ended December 2025. Do the numbers hold clues to what lies ahead for the stock?
Niagen Bioscience (NAGE) Tops Q4 Earnings and Revenue Estimates
Niagen Bioscience (NAGE) delivered earnings and revenue surprises of +100.00% and +8.81%, respectively, for the quarter ended December 2025. Do the numbers hold clues to what lies ahead for the stock?